Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Nivolumab Related Toxicity”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableLooking for participantsNCT05652673
What this trial is testing

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Who this might be right for
Melanoma Stage IVMelanoma Stage IIIImmunotherapy+1 more
Erasmus Medical Center 80
Not applicableUnknownNCT04595734
What this trial is testing

Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

Who this might be right for
Lung Cancer Stage IVLung Cancer, Non-small CellHepatitis
Western Sydney Local Health District 500
Not applicableUnknownNCT05564923
What this trial is testing

CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab

Who this might be right for
Nivolumab Related Toxicity
Namik Kemal University 100
Early research (Phase 1)Not Yet RecruitingNCT07838974
What this trial is testing

Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older

Who this might be right for
Melanoma
University of Southern California 40
Not applicableStudy completedNCT06440811
What this trial is testing

Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Immune-related Adverse EventChemotherapeutic ToxicityGastric or Gastroesophageal Junction Adenocarcinoma
Xijing Hospital 120
Testing effectiveness (Phase 2)UnknownNCT03638375
What this trial is testing

TIL and Anti-PD1 in Metastatic Melanoma

Who this might be right for
Toxicity, DrugAdverse Drug EventEffects of Immunotherapy
Leiden University 34